<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4214">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605588</url>
  </required_header>
  <id_info>
    <org_study_id>Pro2020001862</org_study_id>
    <nct_id>NCT04605588</nct_id>
  </id_info>
  <brief_title>A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19</brief_title>
  <acronym>TriACT</acronym>
  <official_title>A Triple Combination Antiviral Coronavirus Therapy (TriACT) RCT Comparing Nitazoxanide, Ribavirin and Hydroxychloroquine vs. Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rutgers, The State University of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SynaVir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a&#xD;
      combination of three medications currently used to treat other viral infections could be&#xD;
      effective in fighting this new virus. The purpose of this trial is to evaluate the efficacy&#xD;
      of Nitazoxanide (NTZ), Ribavirin (RBV) and Hydroxychloroquine (HCQ) versus placebo in&#xD;
      participants with proven SARS-CoV-2 infection&#xD;
&#xD;
      The study will enroll 70 participants within the 7 days after having been diagnosed with&#xD;
      coronavirus infection. The purpose is to determine if those randomized to 5-day dosing with&#xD;
      the three medication combination have decreased viral load and severity of illness in the 10&#xD;
      days following treatment as compared to those taking placebo. Participants will be actively&#xD;
      followed for 28 days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized into one of two treatment plans&#xD;
&#xD;
        -  Triple combination:&#xD;
&#xD;
             -  Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)&#xD;
&#xD;
             -  Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)&#xD;
&#xD;
             -  Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)&#xD;
&#xD;
        -  No active Medication:&#xD;
&#xD;
             -  Placebo administered according to the above schedule&#xD;
&#xD;
      Viral load (qPCR via nasal swab) will be assessed at baseline (day 0) as well as at days 3,&#xD;
      6, and 10 to monitor response to antiviral treatment. Immune status will be determined by&#xD;
      antibody testing of blood collected at baseline and day 28. Symptom questionnaires will be&#xD;
      completed daily for 10 days and day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Study medication will be tablets/capsules containing either active drug or placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of decline in viral load over the 10 days after randomization</measure>
    <time_frame>10 days after randomization</time_frame>
    <description>qPCR measured via nasal swab</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>SARS-CoV Infection</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Active Study Drug</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 day dosing of Nitazoxanide, Ribavirin &amp; Hydroxychloroquine sulfate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 day dosing of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitazoxanide</intervention_name>
    <description>Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)</description>
    <arm_group_label>Active Study Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Nitazoxanide</intervention_name>
    <description>Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)</description>
    <arm_group_label>Active Study Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Ribavirin</intervention_name>
    <description>Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)</description>
    <arm_group_label>Active Study Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Hydroxychloroquine</intervention_name>
    <description>Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented SARS-CoV-2 infection by qPCR assay performed within the past 7 days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  COVID-19 symptoms requiring hospitalization&#xD;
&#xD;
          -  PO2 &lt; 92%&#xD;
&#xD;
          -  Short of breath at time of enrollment&#xD;
&#xD;
          -  Retinal eye disease&#xD;
&#xD;
          -  Known glucose-6 phosphate dehydrogenase (G-6-PD) deficiency&#xD;
&#xD;
          -  Known chronic kidney disease, stage - 5 or receiving dialysis&#xD;
&#xD;
          -  Current use of:&#xD;
&#xD;
               -  Class 3 AAD (amiodarone, dronaderone, dofetilide, sotalol)&#xD;
&#xD;
               -  Class 1A AAD (procainamide, quinidine, disopyramide)&#xD;
&#xD;
               -  Flecainide&#xD;
&#xD;
               -  SSRI: citalopram (Celexa), Escitalopram (Lexapro)&#xD;
&#xD;
               -  chlorpromazine&#xD;
&#xD;
               -  Cilostazol (Pletal)&#xD;
&#xD;
               -  Donepezil (Aricept)&#xD;
&#xD;
               -  Droperidol&#xD;
&#xD;
               -  Fluoconazole&#xD;
&#xD;
               -  Methadone&#xD;
&#xD;
               -  Ondansetron (Zofran)&#xD;
&#xD;
               -  Thioridazine&#xD;
&#xD;
               -  Macrolides (clarithromycin, erythromycin)&#xD;
&#xD;
               -  Fluroquinolones (ciprofloxacin, levofloxacin, moxifloxacin)&#xD;
&#xD;
               -  Tamoxifen&#xD;
&#xD;
          -  Pregnancy or women who are breast feeding&#xD;
&#xD;
          -  Inability to tolerate oral medications&#xD;
&#xD;
          -  Allergy or prior adverse reaction to either hydroxychloroquine sulfate, ribavirin, or&#xD;
             nitazoxanide&#xD;
&#xD;
          -  Allergy to adhesives&#xD;
&#xD;
          -  QTc interval &gt; 450 mSEC for men and women&#xD;
&#xD;
          -  History of Torsade de Pointes VT or prior cardiac arrest or congenital long QT&#xD;
             interval&#xD;
&#xD;
          -  Non-English-speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey L Carson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey L Carson, MD</last_name>
    <phone>7322357122</phone>
    <email>jeffrey.carson@rutgers.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helaine Noveck, MPH</last_name>
    <phone>7322356581</phone>
    <email>Helaine.Noveck@rutgers.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey L Carson, MD</last_name>
      <phone>732-235-7122</phone>
      <email>jeffrey.carson@rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey L Carson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rutgers, The State University of New Jersey</investigator_affiliation>
    <investigator_full_name>Jeffrey L Carson, MD</investigator_full_name>
    <investigator_title>Distinguished Professor of Medicine, Robert Wood Johnson Medical School</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Nitazoxanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

